The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
The Minimal Important Difference in the 6-Minute Walk Test for Patients with Pulmonary Arterial Hypertension
Open accessAbstract
RATIONALE: Although commonly used as the primary outcome measure of clinical trials in pulmonary arterial hypertension (PAH), the minimal important difference (MID) of the 6-minute walk test (6MWT) has not been well defined for this population of patients. OBJECTIVES: To estimate the MID in the 6MWT in patients with PAH. METHODS: Study subjects from the clinical trial of tadalafil in PAH, a 16-week, parallel-group, randomized clinical trial of patients who were treatment naive or on background therapy with an endothelin receptor antagonist, were eligible. 6MWT was performed using a standardized protocol. Distributional and anchor-based methods were used to estimate the MID; the latter method used the Physical Component Summary Score (PCS) of the Medical Outcomes Study 36-item short form (SF-36). MEASUREMENTS AND MAIN RESULTS: Four hundred five subjects were analyzed. Domains of the SF-36 were weakly to modestly associated with 6MWT. Change in the PCS of the SF-36 was most strongly associated with change in 6MWT (r = 0.40, P < 0.001) and thus was selected as the anchor for subsequent anchor-based analyses. Distributional analyses yielded estimates of the MID ranging from 25.1 to 38.5 m, whereas anchor-based analyses yielded an estimate of 38.6 m. CONCLUSIONS: Using both distributional and anchor-based methods, the estimated consensus MID in the 6MWT for PAH is approximately 33 m. These results have important implications for (1) assessing treatment responses from clinical trials and metaanalyses of specific PAH therapy, and (2) sample size calculations for future study design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700 · cited 1×
“Age, yr 55 (15) 54 (16) 53 (15) 52 (15) 53 (15) 54 (15) Women, n (%) 65 (79) 64 (78) 68 (84) 62 (76) 59 (75) 318 (78) White, n (%) 73 (88) 65 (80) 65 (80) 61 (76) 64 (82) 327 (81) PAH etiology, n (,%) Idiopathic 54 (66) 45 (55) 52 (64) 50 (61) 46 (58) 247 (61) Collagen vascular 16 (20) 16 (20) 24 (30) 21 (26) 19 (24)…”
McHorney, C. A., Ware, J. E., Rachel Lu, J. F., & Sherbourne, C. D. (1994) · Medical Care · doi:10.1097/00005650-199401000-00004 · Cited by 4,458
Bosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Meaningful change and responsiveness in common physical performance measures in older adults.
Perera, S., Mody, S. H., Woodman, R. C., & Studenski, S. A. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00701.x · Cited by 2,513
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Effect Sizes for Interpreting Changes in Health Status
Kazis, L. E., Anderson, J. J., & Meenan, R. F. (1989) · Medical Care · doi:10.1097/00005650-198903001-00015 · Cited by 2,401 · cited 1×
“ES is defined as the average of the difference between end-of-treatment and baseline scores divided by the SD of the baseline scores (29).”
BackgroundRevicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.012 · Cited by 2,362
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,360
Methods to Explain the Clinical Significance of Health Status Measures
Guyatt, G. H., Osoba, D., Wu, A. W., Wyrwich, K. W., & Norman, G. R. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.4.371 · Cited by 1,500
SIMONNEAU, G., BARST, R. J., GALIE, N., NAEIJE, R., RICH, S., BOURGE, R. C., KEOGH, A., OUDIZ, R., FROST, A., BLACKBURN, S. D., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2106079 · Cited by 1,441
Tadalafil Therapy for Pulmonary Arterial Hypertension
Galiè, N., Brundage, B. H., Ghofrani, H. A., Oudiz, R. J., Simonneau, G., Safdar, Z., Shapiro, S., White, R. J., Chan, M., Beardsworth, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.839274 · Cited by 1,103
Galiè, N., Olschewski, H., Oudiz, R. J., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.742510 · Cited by 1,083
Redelmeier, D. A., Bayoumi, A. M., Goldstein, R. S., & Guyatt, G. H. (1997) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.155.4.9105067 · Cited by 1,029 · cited 2×
“Age, yr 55 (15) 54 (16) 53 (15) 52 (15) 53 (15) 54 (15) Women, n (%) 65 (79) 64 (78) 68 (84) 62 (76) 59 (75) 318 (78) White, n (%) 73 (88) 65 (80) 65 (80) 61 (76) 64 (82) 327 (81) PAH etiology, n (,%) Idiopathic 54 (66) 45 (55) 52 (64) 50 (61) 46 (58) 247 (61) Collagen vascular 16 (20) 16 (20) 24 (30) 21 (26) 19 (24)…”
BackgroundWyrwich, K. W., Tierney, W. M., & Wolinsky, F. D. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00071-2 · Cited by 862
van de Veerdonk, M. C., Kind, T., Marcus, J. T., Mauritz, G.-J., Heymans, M. W., Bogaard, H.-J., Boonstra, A., Marques, K. M. J., Westerhof, N., & Vonk-Noordegraaf, A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.068 · Cited by 846
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
Humbert, M., Barst, R. J., Robbins, I. M., Channick, R. N., Galiè, N., Boonstra, A., Rubin, L. J., Horn, E. M., Manes, A., & Simonneau, G. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00028404 · Cited by 640
Simonneau, G., Rubin, L. J., Galiè, N., Barst, R. J., Fleming, T. R., Frost, A. E., Engel, P. J., Kramer, M. R., Burgess, G., Collings, L., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-8-200810210-00004 · Cited by 616
Beaton, D. E., Boers, M., & Wells, G. A. (2002) · Current Opinion in Rheumatology · doi:10.1097/00002281-200203000-00006 · Cited by 513
Holland, A. E., Hill, C. J., Rasekaba, T., Lee, A., Naughton, M. T., & McDonald, C. F. (2010) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2009.10.017 · Cited by 487
Bois, R. M. D., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201007-1179oc · Cited by 465
The right ventricle in pulmonary hypertension
Chin, K. M., Kim, N. H. S., & Rubin, L. J. (2005) · Coronary Artery Disease · doi:10.1097/00019501-200502000-00003 · Cited by 429
The minimal important difference of exercise tests in severe COPD
Puhan, M. A., Chandra, D., Mosenifar, Z., Ries, A., Make, B., Hansel, N. N., Wise, R. A., & Sciurba, F. (2011) · European Respiratory Journal · doi:10.1183/09031936.00063810 · Cited by 402
Self-citationInterpretation of treatment changes in 6-minute walk distance in patients with COPD
Puhan, M. A., Mador, M. J., Held, U., Goldstein, R., Guyatt, G. H., & Schünemann, H. J. (2008) · European Respiratory Journal · doi:10.1183/09031936.00140507 · Cited by 373 · cited 3×
“Age, yr 55 (15) 54 (16) 53 (15) 52 (15) 53 (15) 54 (15) Women, n (%) 65 (79) 64 (78) 68 (84) 62 (76) 59 (75) 318 (78) White, n (%) 73 (88) 65 (80) 65 (80) 61 (76) 64 (82) 327 (81) PAH etiology, n (,%) Idiopathic 54 (66) 45 (55) 52 (64) 50 (61) 46 (58) 247 (61) Collagen vascular 16 (20) 16 (20) 24 (30) 21 (26) 19 (24)…”
MethodSelf-citationThe minimal detectable change cannot reliably replace the minimal important difference
Turner, D., Schünemann, H. J., Griffith, L. E., Beaton, D. E., Griffiths, A. M., Critch, J. N., & Guyatt, G. H. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.01.024 · Cited by 356
End Points and Clinical Trial Design in Pulmonary Arterial Hypertension
McLaughlin, V. V., Badesch, D. B., Delcroix, M., Fleming, T. R., Gaine, S. P., Galiè, N., Gibbs, J. S. R., Kim, N. H., Oudiz, R. J., Peacock, A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.007 · Cited by 251
O’Keeffe, S. T., Lye, M., Donnellan, C., & Carmichael, D. N. (1998) · Heart · doi:10.1136/hrt.80.4.377 · Cited by 250
Macchia, A., Marchioli, R., Marfisi, R., Scarano, M., Levantesi, G., Tavazzi, L., & Tognoni, G. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.02.037 · Cited by 232
Determination of the clinical importance of study results: A review
Man-Son-Hing, M., Laupacis, A., O’Rourke, K., Molnar, F. J., Mahon, J., Chan, K. B. Y., & Wells, G. (2002) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2002.11111.x · Cited by 180
Small changes in six-minute walk distance are important in diffuse parenchymal lung disease
Holland, A. E., Hill, C. J., Conron, M., Munro, P. E., & McDonald, C. F. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.04.024 · Cited by 144
Clinically Significant Change in Stroke Volume in Pulmonary Hypertension
van Wolferen, S. A., van de Veerdonk, M. C., Mauritz, G.-J., Jacobs, W., Marcus, J. T., Marques, K. M., Bronzwaer, J. G. F., Heymans, M. W., Boonstra, A., Postmus, P. E., et al. (2010) · CHEST Journal · doi:10.1378/chest.10-1066 · Cited by 122
Puhan, M. A., Guyatt, G. H., Goldstein, R., Mador, J., McKim, D., Stahl, E., Griffith, L., & Schünemann, H. J. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2006.04.023 · Cited by 120
Self-citationBarst, R. J., Oudiz, R. J., Beardsworth, A., Brundage, B. H., Simonneau, G., Ghofrani, H. A., Sundin, D. P., & Galiè, N. (2011) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.11.009 · Cited by 104
Chan, K. B. Y., Man‐Son‐Hing, M., Molnar, F., & Laupacis, A. (2001) · Europe PMC (PubMed Central) · Cited by 102
Leidy, N. K., & Wyrwich, K. W. (2005) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050508 · Cited by 98
Sildenafil Improves Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension*
Pepke‐Żaba, J., Gilbert, C. E., Collings, L., & Brown, M. C. J. (2008) · CHEST Journal · doi:10.1378/chest.07-0592 · Cited by 96
Gilbert, C. E., Brown, M. C. J., Cappelleri, J. C., Carlsson, M. O., & McKenna, S. P. (2008) · CHEST Journal · doi:10.1378/chest.07-0275 · Cited by 85
Quantifying responsiveness of quality of life measures without an external criterion
Zou, G. (2005) · Quality of Life Research · doi:10.1007/s11136-004-0027-4 · Cited by 67
Cited by
Riociguat for the treatment of pulmonary arterial hypertension
Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209655 · Cited by 1,346
Singh, S. J., Puhan, M. A., Andrianopoulos, V., Hernandes, N. A., Mitchell, K. E., Hill, C. J., Lee, A. L., Camillo, C. A., Troosters, T., Spruit, M. A., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00150414 · Cited by 935
Self-citationHoeper, M. M., Barst, R. J., Bourge, R. C., Feldman, J., Frost, A. E., Galié, N., Gómez-Sánchez, M. A., Grimminger, F., Grünig, E., Hassoun, P. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000765 · Cited by 574
Pulmonary Arterial Hypertension: The Clinical Syndrome
Lai, Y.-C., Potoka, K. C., Champion, H. C., Mora, A. L., & Gladwin, M. T. (2014) · Circulation Research · doi:10.1161/circresaha.115.301146 · Cited by 402
Treatment Goals of Pulmonary Hypertension
McLaughlin, V. V., Gaine, S. P., Howard, L. S., Leuchte, H. H., Mathier, M. A., Mehta, S., Palazzini, M., Park, M. H., Tapson, V. F., & Sitbon, O. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.034 · Cited by 294
Metadata
- Authors
- Mathai, S. C., Puhan, M. A., Lam, D., & Wise, R. A.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-09-01
- Volume
- 186
- Issue
- 5
- Pages
- 428-433
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2004950293
- Cited by
- 276
- References
- 39
- FWCI
- 16.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.